Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%

Simple item page
dc.contributor.authorSpira, A.
dc.contributor.authorPlanchard, D.
dc.contributor.authorCho, B. C.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorDaniel, D.
dc.contributor.authorVillegas, A.
dc.contributor.authorVicente, D.
dc.contributor.authorHui, R.
dc.contributor.authorMurakami, S.
dc.contributor.authorPaz-Ares, L.
dc.contributor.authorBoothman, A.
dc.contributor.authorPoole, L.
dc.contributor.authorWadsworth, C.
dc.contributor.authorDennis, P.
dc.contributor.authorAntonia, S.
dc.contributor.authoraffiliation[Spira, A.] Virginia Canc Specialists, Fairfax, VA USA
dc.contributor.authoraffiliation[Planchard, D.] Inst Gustave Roussy, Villejuif, France
dc.contributor.authoraffiliation[Cho, B. C.] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
dc.contributor.authoraffiliation[Ozguroglu, M.] Istanbul Univ, Cerrahpasa Med Sch, Istanbul, Turkey
dc.contributor.authoraffiliation[Daniel, D.] Tennessee Oncol, Nashville, TN USA
dc.contributor.authoraffiliation[Daniel, D.] Sarah Cannon Res Inst, Nashville, TN USA
dc.contributor.authoraffiliation[Villegas, A.] Canc Specialists North Florida, Jacksonville, FL USA
dc.contributor.authoraffiliation[Vicente, D.] Hosp Univ Virgen Macarena, Seville, Spain
dc.contributor.authoraffiliation[Hui, R.] Westmead Hosp, Sydney, NSW, Australia
dc.contributor.authoraffiliation[Hui, R.] Univ Sydney, Sydney, NSW, Australia
dc.contributor.authoraffiliation[Murakami, S.] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
dc.contributor.authoraffiliation[Paz-Ares, L.] Univ Complutense, Ciberonc, Hosp Univ 12 Octubre, Madrid, Spain
dc.contributor.authoraffiliation[Paz-Ares, L.] Cnio, Madrid, Spain
dc.contributor.authoraffiliation[Boothman, A.] Astrazeneca, Cambridge, England
dc.contributor.authoraffiliation[Poole, L.] Astrazeneca, Cambridge, England
dc.contributor.authoraffiliation[Wadsworth, C.] Astrazeneca, Alderley Pk, England
dc.contributor.authoraffiliation[Dennis, P.] Astrazeneca, Gaithersburg, MD USA
dc.contributor.authoraffiliation[Antonia, S.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
dc.date.accessioned2025-01-07T16:01:02Z
dc.date.available2025-01-07T16:01:02Z
dc.date.issued2018-10-01
dc.identifier.doi10.1016/j.jtho.2018.08.975
dc.identifier.essn1556-1380
dc.identifier.issn1556-0864
dc.identifier.unpaywallURLhttp://www.jto.org/article/S1556086418319336/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27563
dc.identifier.wosID454014502128
dc.issue.number10
dc.issue.numberS
dc.journal.titleJournal of thoracic oncology
dc.journal.titleabbreviationJ. thorac. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.organizationSAS - Hospital Universitario Virgen Macarena
dc.page.numberS629-S630
dc.publisherElsevier science inc
dc.rights.accessRightsopen access
dc.subjectdurvalumab
dc.subjectPACIFIC
dc.subjectPD-L1
dc.titleExpanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number13
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen del Rocío
SAS - Hospital Universitario Virgen Macarena

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía